Moderna will start producing a retooled version of its coronavirus vaccine in the Netherlands, doubling the company’s expected EU production, the company announced today.
The new contract, inked with the subcontractor Lonza, will allow Moderna to make approximately 300 million doses a year starting at the end of 2021. The Dutch site, in addition to a drug-substance site run by Rovi in Spain, will allow Moderna to make 600 million doses a year in the EU.
Currently, the American company doesn’t make any drug substance in the EU. Instead, it has outsourced its vaccine substance production to Lonza’s site in Switzerland to supply the EU, U.K. and Canada. But production issues there forced the company to cut projected deliveries to the U.K. and Canada earlier this year.
The company supplied 10 million doses to the EU at the end of March, and is expected to supply 35 million doses by the end of June.
Moderna’s expected 600 million dose estimate is based on whether its retooled vaccine requires 50 micrograms of drug substance per dose and is approved by the regulators. The company is trialing retooled versions of its vaccine, which has been approved in the EU since early January.